News

ascopubs.org3d
Multicenter real-world study of trastuzumab combined with pirotinib or pertuzumab as a neoadjuvant therapy for stage II-III HER-2 positive breast cancer.
Outcomes from targeted axillary lymph node dissection after neoadjuvant chemotherapy for breast cancer in a safety-net medical center. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
ascopubs.org3d
HER2DX genomic test in HER2-positive breast cancer treated with 15 weeks of neoadjuvant paclitaxel, trastuzumab, and pertuzumab (THP): Final analysis from the BiOnHER clinical ...
Results of the prospective randomized controlled trial VOG-01: Neoadjuvant endocrine therapy ribociclib + fulvestrant + GnRH-a versus chemotherapy 4 AC + 4 T for early HR+/HER2-negative breast cancer ...
Targeted Oncology1d
Tolaney’s ‘What to Watch’: Key Breast Cancer Abstracts at ASCO 2025
Sara M. Tolaney, MD, MPH, highlights a transformative year for breast cancer research at this year’s ASCO Annual Meeting.